Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-07
DOI
10.1038/s41467-021-26112-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential Regulation of Type I and Type III Interferon Signaling
- (2019) Megan L. Stanifer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A coiled-coil masking domain for selective activation of therapeutic antibodies
- (2019) Vivian H. Trang et al. NATURE BIOTECHNOLOGY
- Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
- (2019) Jian Qiao et al. CANCER CELL
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
- (2018) Chien-Chun Steven Pai et al. JOURNAL OF CLINICAL INVESTIGATION
- STING, DCs and the link between innate and adaptive tumor immunity
- (2017) Ralph E. Vatner et al. MOLECULAR IMMUNOLOGY
- Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes
- (2016) Cherie T. Ng et al. CELL
- Effects of radiation on metastasis and tumor cell migration
- (2016) Marta Vilalta et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
- (2015) David Anz et al. CANCER RESEARCH
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- Anti-CD20-Interferon-β Fusion Protein Therapy of Murine B-Cell Lymphomas
- (2013) Kham R. Trinh et al. JOURNAL OF IMMUNOTHERAPY
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
- (2012) Bradley N Bidwell et al. NATURE MEDICINE
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- Interferon-α as angiogenesis inhibitor: Learning from tumor models
- (2010) Stefano Indraccolo AUTOIMMUNITY
- Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
- (2010) Kai Kessenbrock et al. CELL
- Type I interferon: friend or foe?
- (2010) Giorgio Trinchieri JOURNAL OF EXPERIMENTAL MEDICINE
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
- (2009) M. Gobert et al. CANCER RESEARCH
- Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma
- (2008) Axel Hauschild et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now